Comparative Pharmacology
Head-to-head clinical analysis: LACTULOSE versus TURGEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LACTULOSE versus TURGEX.
LACTULOSE vs TURGEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a non-absorbable disaccharide that is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, resulting in an osmotic effect that increases stool water content and softens stools. In hepatic encephalopathy, lactulose acidifies the colonic lumen, converting NH3 to NH4+, which is poorly absorbed, and reduces systemic ammonia levels.
TURGEX is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin into presynaptic neurons.
Constipation: 15-30 mL (10-20 g) orally once daily, increased to 45-60 mL (30-40 g) daily if needed. Hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily; titrate to produce 2-3 soft stools daily.
10 mg orally once daily
None Documented
None Documented
Clinical Note
moderateL-Glutamine + Lactulose
"The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine."
1-2 hours (terminal elimination half-life for lactulose). However, its clinical effect is not dependent on systemic half-life; the drug acts locally in the colon.
Terminal half-life 8.2 ± 1.5 hours; extends to 15–20 hours in moderate hepatic impairment (Child-Pugh B) and to 12–14 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment
Primarily fecal (unaltered, >90%). Minimal renal excretion (<5% as metabolites). Very small amount (approximately 3%) excreted in urine as unchanged drug.
Approximately 70% renal (60% unchanged, 10% as inactive glucuronide conjugate), 20% fecal via biliary elimination, and 10% metabolized by hepatic CYP3A4 to minor metabolites
Category C
Category C
Laxative
Laxative